DAWN240517C12500
- 4.60
- 0.000.00%
Day One Biopharmaceuticals Newsroom
BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda
BrightSpring Health Services (BTSG) said Monday its oncology pharmacy Onco360 has partnered with Day One Biopharmaceuticals (DAWN) to become a specialty provider of Ojemda, a treatment for children wi
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$126.59K in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer Bender Jeremy sold 7,873 shares of common stock on May 16, 2024 at an average price of $16.0787 for a total value of $126.59K.Source: Announcement What is
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$36,450.41 in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer Blackman Samuel C. sold 2,267 shares of common stock on May 16, 2024 at an average price of $16.0787 for a total value of $36,450.41.Source: Announcement
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$43,010.52 in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer York Charles N II sold 2,675 shares of common stock on May 16, 2024 at an average price of $16.0787 for a total value of $43,010.52.Source: Announcement W
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$52,304.01 in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer Dubow Adam sold 3,253 shares of common stock on May 16, 2024 at an average price of $16.0787 for a total value of $52,304.01.Source: Announcement What is
Form 144 | Day One Biopharmaceuticals(DAWN.US) Officer Proposes to Sell 126.59K in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $Day One Biopharmaceuticals(DAWN.US)$ Officer JEREMY BENDER intends to sell 7,873 shares of its common stock on May 16, with a total market value of approximately $126.
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$163.74K in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer Blackman Samuel C. sold 10,000 shares of common stock on May 10, 2024 at an average price of $16.3743 for a total value of $163.74K.Source: Announcement W
Bank of America Securities Reaffirms Their Sell Rating on Day One Biopharmaceuticals (DAWN)
Buy Rating on Day One Biopharmaceuticals: Ojemda's Market Potential and Strategic Commercialization
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
Express News | Day One Biopharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $40 From $50
Express News | Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Day One Biopharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 98.19% Needham → $33 Reiterates Buy → Buy 04/25/2024 98.19% Needham → $33 Reiterates Buy → Buy
Express News | Day One Biopharmaceuticals Inc Q1 Shr View $-0.66 -- Lseg Ibes Data
Express News | Day One Biopharmaceuticals Inc: Qtrly Shr Loss $0.72
Express News | Day One Biopharmaceuticals Inc: Believes It Has Sufficient Capital Resources to Fund Anticipated Operations Into 2026
Express News | Day One Biopharmaceuticals Inc: Cash Position: Cash, Cash Equivalents and Short-Term Investments Totaled $317.9 Mln on March 31, 2024
Day One Biopharm 1Q Loss/Shr 72c >DAWN
Day One Biopharm 1Q Loss/Shr 72c >DAWN
Day One Biopharmaceuticals | 10-Q: Quarterly report
Express News | Day One Biopharmaceutical Q1 2024 GAAP EPS $(0.72) Misses $(0.66) Estimate